Anthropic is targeting an October 2026 Nasdaq listing after confidentially filing a draft S-1 with the SEC on June 1, with Goldman Sachs and Morgan Stanley leading the offering and JPMorgan also on the deal team. The company's valuation reached $965 billion following a $65 billion Series H-1 round in May, up sharply from $380 billion at its February Series G, while run-rate revenue reportedly reached $47 billion by May -- up from roughly $9 billion at the end of 2025.
The timing is the story as much as the numbers. OpenAI, Anthropic's chief rival, has pushed its own IPO target from fall 2026 to 2027, a delay that hands Anthropic a genuine opportunity to reach public markets first among frontier AI labs and set the valuation benchmark against which OpenAI, xAI, and every other major lab will subsequently be measured. Being first matters disproportionately in a category this new -- there's no established public comp set for a company Anthropic's size and growth rate, so whatever multiple Anthropic prices at becomes the reference point.
“But SpaceX's own aftermarket performance -- down close to 39% from its post-IPO high -- is the complicating factor Anthropic's bankers can't ignore.”
Bankers now consider a debut above the $1 trillion mark a realistic base case, which would make Anthropic's IPO the second-largest in history behind only SpaceX's $1.77 trillion listing -- both arriving in the same calendar year, an unprecedented concentration of mega-cap tech debuts.
But SpaceX's own aftermarket performance -- down close to 39% from its post-IPO high -- is the complicating factor Anthropic's bankers can't ignore. If public investors are already showing limited patience for execution risk on one AI-adjacent trillion-dollar debut, Anthropic's roadshow will need to make an unusually convincing case that its revenue growth (80x annualized in Q1, by Amodei's own account) is durable rather than a temporary spike from initial enterprise adoption.
What to watch: whether Anthropic holds its October target given SEC review timelines, and whether its roadshow pricing reflects any caution learned from SpaceX's volatile first six weeks as a public company.